IL271665B2 - benzazapine derivatives - Google Patents
benzazapine derivativesInfo
- Publication number
- IL271665B2 IL271665B2 IL271665A IL27166519A IL271665B2 IL 271665 B2 IL271665 B2 IL 271665B2 IL 271665 A IL271665 A IL 271665A IL 27166519 A IL27166519 A IL 27166519A IL 271665 B2 IL271665 B2 IL 271665B2
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- optionally substituted
- ring
- halogen
- group
- Prior art date
Links
- 150000008038 benzoazepines Chemical class 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 claims 34
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 30
- 125000001424 substituent group Chemical group 0.000 claims 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 21
- 125000005843 halogen group Chemical group 0.000 claims 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 18
- 229920006395 saturated elastomer Polymers 0.000 claims 17
- 150000002367 halogens Chemical class 0.000 claims 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000005842 heteroatom Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 125000004076 pyridyl group Chemical group 0.000 claims 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 7
- 125000002950 monocyclic group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 4
- -1 benzazepine compound Chemical class 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 150000002430 hydrocarbons Chemical group 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 3
- 206010003445 Ascites Diseases 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000019025 Hypokalemia Diseases 0.000 claims 2
- 206010021036 Hyponatraemia Diseases 0.000 claims 2
- 208000027530 Meniere disease Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 229910052805 deuterium Inorganic materials 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000008284 inappropriate ADH syndrome Diseases 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims 2
- 208000024896 potassium deficiency disease Diseases 0.000 claims 2
- 230000008085 renal dysfunction Effects 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 229930192474 thiophene Natural products 0.000 claims 2
- 125000000169 tricyclic heterocycle group Chemical group 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- LYTKGVODDQJIBU-UHFFFAOYSA-N pyrazine;quinoline Chemical group C1=CN=CC=N1.N1=CC=CC2=CC=CC=C21 LYTKGVODDQJIBU-UHFFFAOYSA-N 0.000 claims 1
- 239000002536 vasopressin receptor antagonist Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2017/024211 WO2019003433A1 (fr) | 2017-06-30 | 2017-06-30 | Dérivé de benzazépine |
| PCT/JP2018/024786 WO2019004421A1 (fr) | 2017-06-30 | 2018-06-29 | Dérivés de benzazépine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL271665A IL271665A (en) | 2020-02-27 |
| IL271665B1 IL271665B1 (en) | 2023-01-01 |
| IL271665B2 true IL271665B2 (en) | 2023-05-01 |
Family
ID=62976113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL271665A IL271665B2 (en) | 2017-06-30 | 2019-12-23 | benzazapine derivatives |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10889570B2 (fr) |
| EP (2) | EP3645513B1 (fr) |
| JP (2) | JP6688436B2 (fr) |
| KR (1) | KR102632228B1 (fr) |
| CN (1) | CN110891939A (fr) |
| AU (1) | AU2018293081B2 (fr) |
| BR (1) | BR112019027678A2 (fr) |
| CA (1) | CA3068396A1 (fr) |
| DK (2) | DK4056557T3 (fr) |
| EA (1) | EA202090131A1 (fr) |
| ES (2) | ES2964569T3 (fr) |
| FI (1) | FI4056557T3 (fr) |
| HR (2) | HRP20221359T1 (fr) |
| HU (2) | HUE060855T2 (fr) |
| IL (1) | IL271665B2 (fr) |
| LT (2) | LT4056557T (fr) |
| PH (1) | PH12020500034A1 (fr) |
| PL (2) | PL3645513T3 (fr) |
| PT (2) | PT4056557T (fr) |
| SA (1) | SA519410888B1 (fr) |
| SG (1) | SG11201912757VA (fr) |
| SI (1) | SI4056557T1 (fr) |
| TW (1) | TWI798234B (fr) |
| WO (2) | WO2019003433A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6868089B2 (ja) * | 2018-12-28 | 2021-05-12 | 大塚製薬株式会社 | 医薬 |
| CA3160645A1 (fr) | 2019-11-07 | 2021-05-14 | The Board Of Trustees Of The University Of Illinois | Inhibiteurs d'entree virale de la grippe |
| CN111450879A (zh) * | 2020-05-08 | 2020-07-28 | 内蒙古自治区石油化工监督检验研究院 | 用于乙炔氢氯化反应的丙二胺改性低钌催化剂及制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5258510A (en) * | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
| EP0716083A1 (fr) * | 1993-08-26 | 1996-06-12 | Yamanouchi Pharmaceutical Co. Ltd. | Derives de la benzazepine, composition pharmaceutique le contenant, et ses intermediaires |
| EP2495236A1 (fr) * | 2009-10-26 | 2012-09-05 | Otsuka Pharmaceutical Co., Ltd. | Composé de benzazépine |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985869A (en) * | 1989-10-20 | 1999-11-16 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic compounds |
| WO1991005549A1 (fr) | 1989-10-20 | 1991-05-02 | Otsuka Pharmaceutical Co., Ltd. | Composes benzoheterocycliques |
| JP2905909B2 (ja) | 1991-04-19 | 1999-06-14 | 大塚製薬株式会社 | バソプレシン拮抗剤 |
| CA2116334A1 (fr) | 1992-07-02 | 1994-01-20 | Hidenori Ogawa | Antagoniste de l'oxytocine |
| AU657431B2 (en) | 1992-08-20 | 1995-03-09 | Otsuka Pharmaceutical Co., Ltd. | Benzoheterocyclic compounds as oxytocin and vasopressin antagonists |
| JP2961291B2 (ja) * | 1992-08-20 | 1999-10-12 | 大塚製薬株式会社 | ベンゾヘテロ環化合物 |
| TW270927B (fr) | 1992-10-16 | 1996-02-21 | Otsuka Pharma Co Ltd | |
| JP2913082B2 (ja) * | 1992-10-16 | 1999-06-28 | 大塚製薬株式会社 | バソプレシン拮抗剤及びオキシトシン拮抗剤 |
| ES2199251T3 (es) | 1994-06-15 | 2004-02-16 | Otsuka Pharmaceutical Company, Limited | Derivados benzoheterociclicos utilizables como moduladores de vasopresina o de oxitocina. |
| JPH09221476A (ja) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
| JPH10120592A (ja) | 1996-10-22 | 1998-05-12 | Otsuka Pharmaceut Co Ltd | メニエール病乃至メニエール症候群治療剤 |
| AUPP150098A0 (en) | 1998-01-27 | 1998-02-19 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| JP4374088B2 (ja) * | 1999-01-14 | 2009-12-02 | 東ソ−・エフテック株式会社 | 新規な４，４−ジフルオロベンゾアゼピンケタール誘導体、およびそれを経由する４，４−ジフルオロベンゾアゼピン−５−オン誘導体の製造方法 |
| EP1627876A1 (fr) * | 2004-08-20 | 2006-02-22 | Ferring B.V. | Composés hétérocycliques condensés et leur usage et leur utilisation comme anti-diurétiques |
| TWI459947B (zh) * | 2007-06-26 | 2014-11-11 | Otsuka Pharma Co Ltd | 苯并氮呯化合物及藥學製劑 |
| US8025813B2 (en) | 2009-11-12 | 2011-09-27 | Rohm And Haas Electronic Materials Cmp Holdings, Inc. | Chemical mechanical polishing composition and methods relating thereto |
| JP2016513112A (ja) * | 2013-02-18 | 2016-05-12 | ザ スクリプス リサーチ インスティテュート | 治療的潜在能力を有するバソプレッシン受容体のモジュレーター |
| TW201605488A (zh) | 2013-10-15 | 2016-02-16 | 大塚製藥股份有限公司 | 用以預防及／或治療多囊腎病之藥物 |
-
2017
- 2017-06-30 WO PCT/JP2017/024211 patent/WO2019003433A1/fr active Application Filing
-
2018
- 2018-06-29 WO PCT/JP2018/024786 patent/WO2019004421A1/fr unknown
- 2018-06-29 LT LTEP22164702.7T patent/LT4056557T/lt unknown
- 2018-06-29 LT LTEPPCT/JP2018/024786T patent/LT3645513T/lt unknown
- 2018-06-29 EP EP18743103.6A patent/EP3645513B1/fr active Active
- 2018-06-29 AU AU2018293081A patent/AU2018293081B2/en active Active
- 2018-06-29 DK DK22164702.7T patent/DK4056557T3/da active
- 2018-06-29 EA EA202090131A patent/EA202090131A1/ru unknown
- 2018-06-29 HU HUE18743103A patent/HUE060855T2/hu unknown
- 2018-06-29 CA CA3068396A patent/CA3068396A1/fr active Pending
- 2018-06-29 PT PT221647027T patent/PT4056557T/pt unknown
- 2018-06-29 TW TW107122567A patent/TWI798234B/zh active
- 2018-06-29 EP EP22164702.7A patent/EP4056557B1/fr active Active
- 2018-06-29 HR HRP20221359TT patent/HRP20221359T1/hr unknown
- 2018-06-29 PT PT187431036T patent/PT3645513T/pt unknown
- 2018-06-29 BR BR112019027678-5A patent/BR112019027678A2/pt active Search and Examination
- 2018-06-29 SI SI201831037T patent/SI4056557T1/sl unknown
- 2018-06-29 HR HRP20231616TT patent/HRP20231616T1/hr unknown
- 2018-06-29 US US16/480,842 patent/US10889570B2/en active Active
- 2018-06-29 ES ES22164702T patent/ES2964569T3/es active Active
- 2018-06-29 SG SG11201912757VA patent/SG11201912757VA/en unknown
- 2018-06-29 KR KR1020207002409A patent/KR102632228B1/ko active IP Right Grant
- 2018-06-29 DK DK18743103.6T patent/DK3645513T3/da active
- 2018-06-29 HU HUE22164702A patent/HUE065010T2/hu unknown
- 2018-06-29 JP JP2019536110A patent/JP6688436B2/ja active Active
- 2018-06-29 CN CN201880041463.9A patent/CN110891939A/zh active Pending
- 2018-06-29 PL PL18743103.6T patent/PL3645513T3/pl unknown
- 2018-06-29 FI FIEP22164702.7T patent/FI4056557T3/fi active
- 2018-06-29 PL PL22164702.7T patent/PL4056557T3/pl unknown
- 2018-06-29 ES ES18743103T patent/ES2932854T3/es active Active
-
2019
- 2019-12-23 IL IL271665A patent/IL271665B2/en unknown
- 2019-12-24 SA SA519410888A patent/SA519410888B1/ar unknown
-
2020
- 2020-01-02 PH PH12020500034A patent/PH12020500034A1/en unknown
- 2020-04-03 JP JP2020067672A patent/JP7055160B2/ja active Active
- 2020-11-24 US US17/103,319 patent/US11673878B2/en active Active
-
2023
- 2023-04-27 US US18/140,348 patent/US20230265073A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5258510A (en) * | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
| EP0716083A1 (fr) * | 1993-08-26 | 1996-06-12 | Yamanouchi Pharmaceutical Co. Ltd. | Derives de la benzazepine, composition pharmaceutique le contenant, et ses intermediaires |
| EP2495236A1 (fr) * | 2009-10-26 | 2012-09-05 | Otsuka Pharmaceutical Co., Ltd. | Composé de benzazépine |
Non-Patent Citations (3)
| Title |
|---|
| AUSTRALIAN GOVERNMENT. DEPARTMENT OF HEALTH AND AGEING., AUSTRALIAN PUBLIC ASSESSMENT REPORT FOR TOLVAPTAN, 31 October 2012 (2012-10-31) * |
| HARBESON, SCOTT L., AND ROGER D. TUNG., DEUTERIUM MEDICINAL CHEMISTRY: A NEW APPROACH TO DRUG DISCOVERY AND DEVELOPMENT., 31 May 2014 (2014-05-31) * |
| KONDO K., ET AL., 7-CHLORO-5-HYDROXY-1-[2-METHYL-4-(2-METHYLBENZOYLAMINO) BENZOYL]-2, 3, 4, 5-TETRAHYDRO-1H-1-BENZAZEPINE (OPC-41061): A POTENT, ORALLY ACTIVE NONPEPTIDE ARGININE VASOPRESSIN V2 RECEPTOR ANTAGONIST., 31 December 1999 (1999-12-31) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271665B2 (en) | benzazapine derivatives | |
| HRP20230400T1 (hr) | Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1 | |
| HRP20192102T1 (hr) | Benzopirazini protiv raka putem inhibicije fgfr kinaza | |
| HRP20211617T1 (hr) | Benzo[b]tiofenski spojevi kao agonisti sting | |
| PH12020551315A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| TN2018000295A1 (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| JP2019530745A5 (fr) | ||
| RU2018103944A (ru) | Производные этинила как модуляторы метаботропного рецептора глутамата | |
| RU2018104092A (ru) | Бициклические лактамы и способы их применения | |
| JP2016523270A5 (fr) | ||
| MX2023000782A (es) | 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia. | |
| PH12015501102A1 (en) | Imidazopyridine compound | |
| AR086019A1 (es) | COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS | |
| RU2013145310A (ru) | Диспиропирролидиновые производные | |
| WO2008125600A3 (fr) | Dérivés de pyrazole utilisés comme modulateurs de p2x7 | |
| RU2015116749A (ru) | Антагонисты mglu2/3 для лечения аутических расстройств | |
| JP2010536842A5 (fr) | ||
| RU2017110211A (ru) | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ-ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ | |
| SI2945620T1 (en) | Nitroxyl donors with improved therapeutic index | |
| WO2015021396A3 (fr) | Composés de benzoxaborole tricyclique et leurs utilisations | |
| IL273188B (en) | Treatment with a combination of chemokine receptor 2 (ccr2) inhibitors and a pd-1/pd-l1 inhibitor | |
| EA201891672A1 (ru) | Соединения и композиции для лечения криптоспоридиоза | |
| AR116880A1 (es) | Compuestos de pirimidinodiona bicíclicos sustituidos con tetrahidropirano, forma polimórfica del mismo y el uso de los mismos para el tratamiento del hcm | |
| MX2018002738A (es) | Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4. | |
| WO2011080751A3 (fr) | Ligands du récepteur nicotinique neuronal de l'acétylcholine α4β2 |